DP
VRTX icon

Diadema Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Diadema Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Sell
3,840
-6,160
-62% -$2.87M 0.29% 69
2025
Q4 		$4.53M Buy
+10,000
New +$4.31M 0.78% 36
2025
Q3 		– Sell
-10,000
Closed -$4.45M – 168
2025
Q2 		$4.45M Buy
+10,000
New +$4.61M 1.36% 26

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Diadema Partners's VRTX Position: Q1 2026 in Review

Diadema Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 62% in Q1 2026, selling an estimated $2.87M and leaving 3,840 shares worth $1.71M. The position accounts for 0.29% of the portfolio, ranked #69.

Diadema Partners first reported a position in VRTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $4.53M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Diadema Partners held 3,840 shares of Vertex Pharmaceuticals worth $1.71M as of Q1 2026.
  • Diadema Partners sold 6,160 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.87M.
  • Vertex Pharmaceuticals made up 0.29% of Diadema Partners's portfolio in Q1 2026, its #69 holding.
  • Diadema Partners first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Diadema Partners's Vertex Pharmaceuticals position peaked at $4.53M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.